PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
0.49%
Gross profit growth under 50% of AGEN's 6.35%. Michael Burry would be concerned about a severe competitive disadvantage.
56.85%
EBIT growth 50-75% of AGEN's 100.00%. Martin Whitman would suspect suboptimal resource allocation.
54.90%
Operating income growth under 50% of AGEN's 172.09%. Michael Burry would be concerned about deeper cost or sales issues.
56.85%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
56.86%
EPS growth above 1.5x AGEN's 2.91%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
56.86%
Diluted EPS growth above 1.5x AGEN's 2.91%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.00%
Share reduction while AGEN is at 14.91%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while AGEN is at 14.91%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
28.81%
OCF growth 1.25-1.5x AGEN's 21.06%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
28.81%
FCF growth 1.25-1.5x AGEN's 21.06%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
95.99%
10Y OCF/share CAGR 1.25-1.5x AGEN's 78.66%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
56.40%
5Y OCF/share CAGR at 50-75% of AGEN's 83.73%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
-114.69%
Negative 3Y OCF/share CAGR while AGEN stands at 77.37%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
96.39%
Similar net income/share CAGR to AGEN's 90.59%. Walter Schloss would see parallel tailwinds or expansions for both firms.
45.76%
5Y net income/share CAGR at 50-75% of AGEN's 82.26%. Martin Whitman might see a shortfall in operational efficiency or brand power.
32.63%
Below 50% of AGEN's 73.35%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
-96.80%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-86.34%
Negative 5Y equity/share growth while AGEN is at 85.87%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-81.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.20%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-26.00%
We have a declining book value while AGEN shows 72.27%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-9.98%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-36.64%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-70.64%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.